Amgen, Bivitrum announce $130 million sales/licensing deal
LOS ANGELES Amgen announced Monday that it will sell two of its drugs and license another to Biovitrum.
The deal with the Swedish drug maker is worth $130 million. Biovitrum will buy Kepivance and Stemgen and receive exclusive rights to market Kineret. Kepivance is used to treat mouth sores caused by cancer; Stemgen stimulates stem-cell production in the blood; and Kineret treats rheumatoid arthritis.
Amgen, based in Thousand Oaks, Calif., said the three drugs had combined sales last year of almost $70 million.
Bayer denies takeover rumors
FRANKFURT, Germany Reports of Bayer’s imminent takeover appear greatly exaggerated.
The company’s chief executive officer told a German newspaper that it would not be taken over, amid rumors last week that Pfizer sought to acquire it. But Bayer has a number of drugs in its research pipeline, while many of Pfizer’s blockbuster drugs will soon go off patent, facing competition from generic drug makers.
MyMedSchedule now available to the public
INDIANAPOLIS A service that helps people with organ transplants manage their medication schedules has become available to the public.
MyMedSchedule used to be available only in hospitals, reminding organ transplant recipients to take their medications and helping them avoid errors. People who have received transplants often must take several drugs to avoid rejection of the new organs.
Companies such as Community Health Network and the American Society of Health-System Pharmacists offer similar services.